Methods for isolating propargylated aminoindans
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsAnton Frenkel, Ramy Lidor-Hadas, Eduard Gurevich, Gsan Attili
Life of this patent
Estimating the term…
Abstract
A process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan, a process for isolating from a reaction mixture a crystalline diastereomeric salt of a mono-propargylated aminoindan, and a process for isolating from a reaction mixture a salt of enantiomerically pure N-propargyl-1-aminoindan or a salt of enantiomerically pure 6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan. The corresponding products are also disclosed.
Claims37
A process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan having the structure
- wherein R1 is H, hydroxyl, alkoxy or
- wherein Y is O or S;
- R2 and R3 is each, independently, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally halo substituted, or hydrogen;
- where the reaction mixture further comprises a solvent, a primary aminoindan having the structure
- wherein R1 is defined as above, and a tertiary aminoindan having the structure
- the process comprising
- a) adding an acid to the reaction mixture;
- b) crystallizing the mono-propargylated aminoindan under conditions suitable for the formation of a crystalline salt of the mono-propargylated aminoindan;
- and
- c) recovering the crystalline salt of the mono propargylated aminoindan,
- wherein the process is performed without addition of an organic solvent.
A process for isolating from a reaction mixture a diastereomeric salt of a mono-propargylated aminoindan having the structure
- wherein R1 is H, hydroxyl, alkoxy or
- wherein Y is O or S;
- R2 and R3 is each, independently, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally halo substituted, or hydrogen;
- where the reaction mixture further comprises a solvent, a racemic primary aminoindan having the structure
- wherein R1 is defined as above, and a racemic tertiary aminoindan having the structure
- said process comprising
- a) adding a first acid to the reaction mixture in an amount sufficient to form a crystalline acid addition salt of the primary aminoindan;
- b) removing the crystalline acid addition salt said of the primary aminoindan from the reaction mixture, thereby separating the primary aminoindan from the reaction mixture;
- c) adding a second acid to the reaction mixture under conditions suitable for the formation of the crystalline salt of mono-propargylated aminoindan;
- and
- d) recovering the crystalline salt of the mono-propargylated aminoindan.
A process for isolating from a reaction mixture a diastereomeric salt of a mono-propargylated aminoindan having the structure
- wherein R1 is H, hydroxyl, alkoxy or
- wherein Y is O or S;
- R2 and R3 is each, independently, C1-18 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally halo substituted, or hydrogen;
- where the reaction mixture further comprises a solvent, a racemic primary aminoindan having the structure
- wherein R1 is defined as above, and a racemic tertiary aminoindan having the structure
- said process comprising
- a) adding a chiral acid to the reaction mixture in an amount equivalent to the mono-propargylated aminoindan derivative to form a crude diastereomeric salt of the mono-propargylated aminoindan;
- b) separating the crude diastereomeric salt of the mono-propargylated aminoindan from the reaction mixture;
- c) recrystallizing the crude diastereomeric salt of the mono-propargylated aminoindan in water to isolate crystalline diastereomeric salt of the mono-propargylated aminoindan;
- and
- d) recovering crystalline diastereomeric salt of the mono-propargylated aminoindan.
A process for isolating from a reaction mixture a salt of enantiomerically pure N-propargyl-1-aminoindan or a salt of enantiomerically pure 6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan, wherein the reaction mixture further comprises a primary aminoindan having the structure
- wherein R1 is H or
- and a tertiary aminoindan having the structure
- the process comprising crystallizing the salt of enantiomerically pure N-propargyl-1-aminoindan or the salt of enantiomerically pure 6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1 -aminoindan,
- wherein the process is performed without addition of an organic solvent.
Crystalline rasagiline tartrate salt having an aspect ratio of less than 15.
A pharmaceutical composition comprising crystalline rasagiline tartrate salt having an aspect ratio of less than 15.
Dependencies are inferred from the claim text.